<DOC>
	<DOCNO>NCT03076385</DOCNO>
	<brief_summary>This clinical study ass safety , tolerability immunogenicity VAL-506440 healthy adult subject .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity VAL-506440 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion Agrees comply study procedure provide write informed consent 18 64 year age Body mass index 18 30 kg/m2 Negative urine pregnancy test Screening visit day vaccination . Female subject must either nonchildbearing potential use highly effective method contraception least 2 month Screening Visit 3 week post last vaccination In good health base medical history , physical examination , vital sign measurement laboratory safety test perform prior initial study vaccination Exclusion Any ongoing , symptomatic acute chronic illness require medical surgical care Administration investigational product within 45 day Women pregnant breastfeeding , plan become pregnant study Prior administration investigational agent use formulation similar VAL506440 History serious reaction prior influenza vaccination History GuillainBarr√© Syndrome within 6 week follow previous influenza vaccine Administration live attenuate vaccine within 4 week enrollment , inactive vaccine within 2 week enrollment , plan vaccine within vaccination period Any known suspect immunosuppressive condition , acquire congenital , determined history and/or physical examination Any chronic administration immunosuppressant immunemodifying drug within 6 month prior administration study vaccine Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . Any acute disease time enrollment Any bleeding risk thromboembolic event relate medical history Regular alcohol consumption &gt; 3 units/day , current user illicit drug , history drug/alcohol abuse 1 year screen positive urine drug/alcohol test screen Persons employ capacity involve handle poultry wild bird Unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy within 4 week administration first vaccination , throughout study Had major surgery donation blood blood product within 4 week dose Current smoke 10 cigarette ( equivalent amount tobacco ) per day , within 3 month prior Screening Subject employee Sponsor CRO involve study . Vulnerable subject ( e.g. , subject kept detention ) . Any condition , opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result History autoimmune disease Inadequate Liver Function define AST , ALT , GGT , alkaline phosphatase bilirubin &gt; 1.5xULN Known allergy history anaphylaxis serious adverse reaction constituent study vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VAL-506440</keyword>
	<keyword>H10N8 antigen mRNA</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>